Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Fanning, S.W., Mayne, C.G., Dharmarajan, V., Carlson, K.E., Martin, T.A., Novick, S.J., Toy, W., Green, B., Panchamukhi, S., Katzenellenbogen, B.S., Tajkhorshid, E., Griffin, P.R., Shen, Y., Chandarlapaty, S., Katzenellenbogen, J.A., Greene, G.L.(2016) Elife 5
- PubMed: 26836308 
- DOI: 10.7554/eLife.12792
- Primary Citation of Related Structures:  
4PXM, 4Q13, 4Q50 - PubMed Abstract: 
Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance ...